Dermaliq Therapeutics

Dermaliq Therapeutics is a private, clinical-stage biotech company leveraging its proprietary hyliQ® drug delivery platform to create superior topical dermatology treatments. Its primary focus is on androgenetic alopecia, where its lead asset DLQ01 has shown promising Phase 2a results in men, demonstrating a >500% relative hair count improvement versus vehicle. The company aims to address the significant unmet need in hair loss, particularly for women who lack effective topical options, by enabling targeted follicular delivery of potent drug classes like prostaglandin analogs.

hyliQ®: A proprietary, non-aqueous liquid drug delivery platform using customized carrier molecules to transport actives through the stratum corneum for targeted delivery into specific skin structures (e.g., hair follicles, glands). It is fast-drying, non-greasy, and excludes irritating preservatives or penetration enhancers.

Dermaliq competes in the hair loss treatment market against topical minoxidil (the standard of care), oral finasteride (for men), and a growing pipeline of novel therapies (e.g., JAK inhibitors, other prostaglandin analogs). Its competitive edge is the hyliQ® platform's potential for superior follicular targeting and cosmetic elegance compared to existing oily or irritating formulations.